Asciminib is a small molecule inhibitor designed to target the BCR-ABL1 fusion protein, which is a hallmark of chronic myeloid leukemia (CML). Structurally, asciminib contains a unique chemical scaffold that allows it to bind selectively to the myristoyl pocket of the BCR-ABL1 protein. This binding prevents the activation of BCR-ABL1 and inhibits downstream signaling pathways involved in leukemic cell proliferation and survival.Asciminibs specificity for the myristoyl pocket distinguishes it from traditional tyrosine kinase inhibitors (TKIs) like imatinib, which target the ATP-binding site of BCR-ABL1. This unique mechanism of action contributes to asciminibs efficacy and potential to overcome resistance to other TKIs in CML treatment.Asciminib is primarily used for the treatment of chronic myeloid leukemia (CML), particularly in patients who have developed resistance or intolerance to other TKIs. It is indicated for use in adults with CML that is positive for the Philadelphia chromosome and resistant to or intolerant of at least two prior TKIs. Asciminibs ability to selectively target the myristoyl pocket of the BCR-ABL1 protein makes it effective against many BCR-ABL1 mutations that confer resistance to other TKI
Buy high quality Asciminib from Chemicea Pharmaceuticals. Chemicea Pharmaceuticals is one of the leading manufacturer and exporter of Asciminib.